Showing results (161-170 of 269) with videos related to

Sort By:
Pageof 27
HIV Medicine|February 21, 2024
Framingham risk score based vascular outcomes in acute versus chronic HIV cohorts after 6 years of ARTKathryn Brown Holroyd, Win Min Han, Tanakorn Apornpong, et al.
Journal of the International Association of Providers of AIDS Care|March 12, 2019
An Integrated Approach to HIV Disclosure for HIV-Affected Families in ThailandJureeporn Jantarapakde, Chitsanu Pancharoen, Somsong Teeratakulpisarn, et al.
Hepatology (Baltimore, Md.)|August 13, 2008
A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in ThailandGail V Matthews, Anchalee Avihingsanon, Sharon R Lewin, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 4, 2020
Incident Liver Cirrhosis, Associated Factors, and Cardiovascular Disease Risks Among People Living With HIV: A Longitudinal StudyWin Min Han, Thornthun Ueaphongsukkit, Pairoj Chattranukulchai, et al.
AIDS (London, England)|November 17, 2022
Pro-fibrogenic role of alarmin high mobility group box 1 in HIV-hepatitis B virus coinfectionKasha P Singh, Laura J Pallett, Harsimran Singh, et al.
Antiviral Therapy|August 5, 2008
Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicinAnchalee Avihingsanon, Weerawat Manosuthi, Pacharee Kantipong, et al.
Journal of the International AIDS Society|June 21, 2020
Statins for atherosclerotic cardiovascular disease prevention in people living with HIV in Thailand: a cost-effectiveness analysisDavid C Boettiger, Anthony T Newall, Pairoj Chattranukulchai, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 16, 2014
Cerebrospinal fluid exposure of efavirenz and its major metabolites when dosed at 400 mg and 600 mg once daily: a randomized controlled trialAlan Winston, Janaki Amin, Amanda Clarke, et al.
Pageof 27